CytoDyn Inc (CYDY) Posts Earnings Results, Misses Expectations By $0.03 EPS

CytoDyn Inc (NASDAQ:CYDY) posted its earnings results on Tuesday. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.03), Bloomberg Earnings reports.

Shares of CytoDyn (NASDAQ CYDY) opened at 0.673 on Wednesday. The firm’s market cap is $102.81 million. CytoDyn has a 12-month low of $0.46 and a 12-month high of $0.84. The company has a 50 day moving average of $0.65 and a 200-day moving average of $0.65.

CYDY has been the topic of a number of analyst reports. HC Wainwright set a $2.00 target price on shares of CytoDyn and gave the stock a “buy” rating in a report on Thursday, August 10th. Zacks Investment Research upgraded shares of CytoDyn from a “sell” rating to a “hold” rating in a report on Wednesday, July 19th. Finally, ValuEngine upgraded shares of CytoDyn from a “strong sell” rating to a “sell” rating in a report on Thursday, September 7th.

ILLEGAL ACTIVITY WARNING: “CytoDyn Inc (CYDY) Posts Earnings Results, Misses Expectations By $0.03 EPS” was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.com-unik.info/2017/10/11/cytodyn-inc-cydy-posts-earnings-results-misses-expectations-by-0-03-eps.html.

About CytoDyn

CytoDyn Inc is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.

What are top analysts saying about CytoDyn Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CytoDyn Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit